ObjectiveTo analyze the burden of digestive diseases attributed to smoking in China from 1990 to 2019 and forecast its change in the next 10 years. MethodsThe Global Burden of Disease database 2019 was used to analyze the burden of digestive diseases attributed to smoking in China from 1990 to 2019. Joinpoint regression model was used to analyze the time variation trend. A time series model was used to predict the burden of digestive diseases attributable to smoking over the next 10 years. ResultsIn 2019, there were 12 900 deaths from digestive diseases attributed to smoking in China, with a DALY of 398 600 years, a crude death rate of 0.91/100 000 and a crude DALY rate of 28.02/100 000. The attributed standardized mortality rate was 0.69 per 100 000, and the standardized DALY rate was 19.79 per 100 000, which was higher than the global level. In 2019, the standardized mortality rate and DALY rate of males were higher than those of females (1.48/ 100 000 vs. 0.11/ 100 000, 38.42/ 100 000 vs. 293/100 000), and the standardized rates of males and females showed a downward trend over time. In 2019, both mortality and DALY rates from digestive diseases attributed to smoking increased with age. ARIMA predicts that over the next 10 years, the burden of disease in the digestive system caused by smoking will decrease significantly. ConclusionFrom 1990 to 2019, the burden of digestive diseases attributed to smoking showed a decreasing trend in China, and the problem of disease burden is more serious in men and the elderly population. A series of effective measures should be taken to reduce the smoking rate in key groups. The burden of digestive diseases caused by smoking will be significantly reduced in the next 10 years.
Objective To investigate inpatients disease constitution, costs and rational drug use in the Karamay Central Hospital in 2014 and provide baseline data for further evidence-based study. Methods The information of disease classification, single disease drug use and expenditure of inpatients in 2014 were collected from the Hospital Information System (HIS) of Karamay Central Hospital. We classified the diseases according to the international classification of diseases coding (ICD-10), and analyzed the data by Microsoft Excel 2007 software including frequency, proportion, cumulative proportion and sample average. Results ① A total of 24 936 inpatients in 2014 were included, with male to female ratio being 0.96 to 1 and minority rate being 22.95%. The top three systematic diseases were respiratory diseases, diseases concerning pregnancy, child birth and puerperium and circulatory system diseases respectively; ② The top three age groups were 25 to 59, ≥60 and 0 to 4 respectively; ③ The top three costs per capita of single disease were pulmonary infectious, tumor chemotherapy and symptomatic treatment respectively; the top three western medicine costs per capita were tumor chemotherapy, symptomatic treatment and pulmonary infection; the top three Chinese medicine costs per capita were chronic kidney disease (CKD), angina and ischemic stroke. Conclusion The single diseases ranking and percentage of inpatients in 2014 of Karamay Central Hospital were different from the disease burden of Xinjiang Uygur Autonomous Region, the country and even the whole world. Based on the above results, the respiratory diseases and circulatory diseases were selected as the systematic evidence-based pharmacy study goal.
ObjectivesTo systematically review approaches to derive disability weights (DWs) based on EQ-5D instrument.MethodsPubMed, EMbase, Web of Science, CNKI and WanFang Data databases were electronically searched to collect studies on the approaches to derive disability weights based on EQ-5D from inception to June 1st, 2019. Two reviewers independently screened literature, extracted the basic information and evaluated risk of bias of included studies. Then, systematic review on approaches to derive DWs based on EQ-5D instrument was performed.ResultsA total of 18 studies were included, which were published between 2003 and 2018. The included studies involved a variety of diseases, mostly focusing on quality of life and the burden of disease. The approaches to derive DWs based on EQ-5D health instrument were as follows: DWs=health utility scoreNormal or Control−health utility scoreDisease (7 studies), DWs=1−VAS score/100 (6 studies), DWs=1−health utility scoreDisease (3 studies), linear regression model (1 study), and mapping (1 study).ConclusionsAmong all the included studies using EQ-5D-based disability weight measurement methods involves a variety of diseases, with relatively low comparability. More methodological studies are from abroad. Among all the applied approaches, DWs equally to health utility scoreNormal or Control minus health utility scoreDisease is the most commonly used.
Objective The aim of this study was to describe the trends in the burden of breast cancer in women of all ages in China from 1990 to 2021, compare it with the global burden of breast cancer in women, and predict the burden of disease in the next 15 years. Methods Based on the open data of the Global Burden of Disease (GBD) in 2021, the incidence, prevalence, mortality and disability-adjusted life years (DALYs) of breast cancer among women in China and the world were analyzed. Joinpoint was used to calculate annual percentage change (APC) and average annual percentage change (AAPC) to reflect the changing trend of disease burden. An autoregressive composite moving average (ARIMA) model was used to predict the disease burden of breast cancer in women from 2022 to 2036. Results From 1990 to 2021, the age-standardized incidence rate (ASIR) and age-standardized prevalence rate (ASPR) of female breast cancer in China showed an increasing trend, with an average annual increase of 2.400 7% and 2.334 8%, respectively, and the age-standardized mortality rate (ASMR) and age-standardized DALYs rate (ASDR) showed a decreasing trend. The average annual decline was 0.290 0% and 0.198 3%, respectively. Meanwhile, ASIR and ASPR of global female breast cancer also showed an increasing trend, with an average annual increase of 0.474 9% and 0.3445 2% respectively, while ASMR and ASDR showed a decreasing trend, with an average annual decrease of 0.425 2% and 0.321 8% respectively. Among them, there were differences in the impact of age on the burden of female breast cancer. The peak of ASIR and ASPR appeared in the age group of 50 to 69 years old, and generally increased with the increase of age, and then decreased when reaching the peak. ASMR and ASDR increased with age. In the following 15 years, the prevalence of breast cancer in women in China and globally showed an increasing trend, while the mortality rate showed a decreasing trend. Conclusion From the analysis of the disease burden from 1990 to 2021, breast cancer has a huge harm to women, and the incidence of young and middle-aged women is high, the death rate of middle-aged and elderly women is high, and the disease time is long, which brings a heavy psychological and economic burden to patients and society. From the trend forecast for the next 15 years, the prevalence of breast cancer in women in China and the world will increase, while the mortality rate will decrease slightly, but the decrease is not large, which will bring huge public health challenges and put higher requirements on the prevention and control of the disease. To reduce the disease burden of breast cancer, comprehensive strategies for disease control are needed, including prevention of risk factors at the primary care level, screening of at-risk populations, and quality medical services.
ObjectiveTo analyze the latest epidemiological status of breast cancer in China, trends in morbidity and mortality from 1990 to 2019, and related prognostic risk factors.MethodsData on incidence and mortality of Chinese female breast cancer, their related age-standardized rates (ASRs) from 1990 to 2019, and attributable risk factors were obtained from the Global Burden of Disease (GBD) database, and data on disability-adjusted life years (DALYs) of 34 provinces in China were obtained from literature. Joinpoint regression analysis was used to analyze the trends of ASRs. The exposure levels of each attributable risk factor and the increased cancer burden were analyzed.ResultsThe incidence of breast cancer in Chinese females increased annually, from 17.07/100 000 in 1990 to 35.61/100 000 in 2019, while the mortality rate initially increased and decreased, and then exhibited an upward trend after 2016 and there was no obvious variation from 1990 (9.16/100 000) to 2019 (9.02/100 000). Among the 34 provinces of China, Shandong Province had the most serious breast cancer burden, while Macao Special Administrative Region had the lowest. Among the seven prognostic risk factors, high body mass index (BMI) contributed the most to the breast cancer burden and the exposure risk of a diet high in red meat had shown a significant increasing trend in the past 30 years. Therefore, the disease burden caused by a high red meat diet would be increasing.ConclusionsThe incidence rate of breast cancer in Chinese females is increasing. With the development of social economy and the change of people’s dietary habits, the breast cancer burden in China trends to become heavier and heavier. Therefore, it is necessary to conduct the "three early" prevention and treatment and advocate healthy and reasonable diet and living habits to reduce the burden of breast cancer to improve prognosis and quality of life.
ObjectivesTo systematically review the disease burden and epidemiological characteristics of tuberculosis in the Chinese population, and to provide reference for health resources allocation and health policy making.MethodsDatabases such as PubMed, EMbase, CNKI, VIP and WanFang Data were searched for studies investigating disease burden of tuberculosis in Chinese population from inception to August 1st, 2017. Two researchers independently screened literature, exacted data and assessed methodological quality of included studies. Statistical analysis was performed on data of tuberculosis associated population, mortality and disease burden.ResultsA total of 40 studies were included. The results of qualitative analysis showed that, since 1990, the prevalence of tuberculosis and its disease burden in China decreased year by year. However, the disease burden per patient and the total economic burden in China showed an increasing trend, and the economical disease burden increased 1.6 times from 1993 to 2003. The disease burden of men was higher than that of women, and it was higher in the countryside than in the city. In 2004, the ratio of YLL per thousand people in rural and urban areas was 2.18, and the ratio was 1.29 in 2014. Additionally, the disease burden decreased gradually in western, central and eastern regions. In 2014, compared with 2004, YLL decreased by 1.11, while the central and eastern regions were 0.48 and 0.25, respectively. The gap between the gender, the urban and rural areas and the regions was not as significant as in previous.ConclusionsThe disease burden of tuberculosis in China is seriously high and the tuberculosis prevention and control work should take into consideration the epidemiological characteristics of tuberculosis and the trends of the disease burden. It is necessary to rationally and effectively implement health intervention programs and allocate health resources based on different health demands in different regions and age groups to reduce the morbidity and mortality, and to pay more attention to drug-resistant tuberculosis. Besides, the emphasis of prevention should be placed on reducing disease burden in the elderly and strengthening prevention in the young population.
ObjectiveTo analyze the epidemiological burden and trend of skin malignant melanoma in China based on the data from the global burden of disease 2019 (GBD 2019). MethodsThe data about quantity of incidences/illnesses/deaths, age-standardized incidence/prevalence rates/mortality, disability-adjusted life years (DALYs), and DALY rate of skin malignant melanoma in China from 1990 to 2019 were obtained from the GBD 2019 databases. The epidemiological trends, age-period-cohort trends, and the relationship between the incidence and sociodemographic index (SDI) were analyzed.ResultsIn 2019, both prevalence and incidence of skin malignant melanoma in China were at low levels in the world, the age-standardized mortality ranked the 35th in the 204 countries GBD researched, the number of prevalent cases and incident cases increased compared with 1990 (12.65% and 3.57%, respectively), the prevalence and incidence rates showed growth trends, while the DALY rate and mortality decreased slowly. The prevalence of skin malignant melanoma peaked age at 50 to 54 years old. The incidence peak age of males was older than that of females (55-59 years old for males vs. 50-54 years old for females), while the mortality peak age of males was younger than that of females (55-59 years old for males vs. 75-79 years old for females). With the increasing of SDI value, the incidence of skin malignant melanoma showed a linear growth trend. DALY rate was negatively correlated with SDI (P<0.05). ConclusionFrom 1990 to 2019, age-standardized incidence and prevalence of skin malignant melanoma in China are increasing, while DALY rate and mortality are decreasing, and these are correlated with social and medical development.
ObjectiveTo analyze the disease burden and evolving trends for gastric cancer in China and worldwide from 1990 to 2021. MethodsBased on the 2021 Global Burden of Disease (GBD) database, we analyzed the burden of gastric cancer using indicators such as incidence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lost due to disability (YLDs). Joinpoint regression analysis was used to calculate the average annual percentage change (AAPC) of these indicators to show trends over time. ResultsIn 2021, the standardized incidence rate of gastric cancer was 14.33 (per 100 000) worldwide and 29.05 (per 100 000) in China, with corresponding standardized mortality rates of 11.20 (per 100 000) and 21.51 (per 100 000). The standardized incidence rate of gastric cancer in China trended downward during 1990–2021 (AAPC=–1.61%, P<0.05), but was lower than the global decline (AAPC=–1.77%, P<0.05). During 1990-2021 in China, the rates of standardized DALYs (AAPC=–2.76%, P<0.05), standardized YLLs (AAPC=–2.78%, P<0.05) and standardized YLDs (AAPC= –1.25%, P<0.05) all showed a significant decrease. The global rates of standardized DALYs (AAPC=–2.42%, P<0.05), standardized YLLs (AAPC=–2.44%, P<0.05) and standardized YLDs (AAPC=–1.56%, P<0.05) all showed a significant decrease. These AAPC values above indicated a general attenuation in the gastric cancer burden across all age groups, both in China and worldwide. ConclusionsDespite these signs of a decline in disease burden indicators for gastric cancer in China and worldwide, the number of cases and deaths in gastric cancer remains substantial coupled with the heavy burden on the healthcare system. Therefore, increased efforts in early detection and prevention strategies are of utmost importance to further reduce the impact of this malignant disease.
Recently, sponsored by the Science Popularization Department of the China Anti Cancer Association, jointly organized by the Rehabilitation Branch of the China Anti Cancer Association and the Mijian Digital Cancer Patient Course Management Platform, and co-organized by the Science Popularization Special Committee of the China Anti Cancer Association, The "2022 White Paper on the Quality of Life of Chinese Lung Cancer Patients" has been officially released (herein after referred to as the "White Paper"), which mainly elaborates on the basic situation of Chinese lung cancer patients and the medical, social, and economic impacts caused by the disease. This article interprets the White Paper in order to help the public understand the real situation of lung cancer patients and provide important empirical evidence and valuable insights for the diagnosis, treatment, and rehabilitation of lung cancer in China.
Objective To analyze the prevalence of leukemia in China from 1990 to 2019, predict the incidence, morbidity and mortality of leukemia in China from 2020 to 2040, and provides reference for the formulation of leukemia-related prevention and treatment strategies in China. Methods Based on the 2019 Global Burden of Disease database, the incidence, morbidity and mortality data of leukemia in China from 1990 to 2019 were collected, and the rate of change and annual estimated percentage of change (EAPC) were used to describe the epidemic trend of the disease. The Autoregressive Moving Average (ARIMA) model was used to predict the prevalence of leukemia in China from 2020 to 2040. Results In 2019, the age-standardized incidence, age-standardized prevalence and age-standardized mortality rate of leukemia in China decreased by 17.62%, 10.97%, and 41.56%, respectively, compared with 1990, and an average annual decrease of 1.06%, 0.89%, and 2.05%, respectively (P<0.05). From 1990 to 2019, the reduction age-standardized incidence rate, age-standardized prevalence rate and age-standardized mortality rate in Chinese women (EAPC was 1.56%, 1.38%, and 2.62%, respectively) was higher than that of men (EAPC was 0.61%, 0.43%, and 1.59%, respectively). In 2019, the incidence and prevalence were highest in the age group under 5 years of age, and the mortality rate was the highest in the age group over 80 years old. The prediction results of ARIMA model showed that the age-standardized incidence rate and prevalence of leukemia in China showed an increasing trend from 2020 to 2040, while the age-standardized mortality rate showed a decreasing trend. It is estimated that by 2040, the age-standardized incidence rate, age-standardized prevalence rate, and age-standardized mortality rate of leukemia will be 14.06/100 000, 108.23/100 000, and 2.83/100 000. Conclusions From 1990 to 2019, the age-standardized incidence rate, age-standardized prevalence rate and age-standardized mortality rate of leukemia in China decreased year by year, but they were still at a high level. The prediction results show that the age-standardized incidence rate and age-standardized prevalence rate of leukemia in China will continue to increase from 2020 to 2040, and it is necessary to continue to strengthen the surveillance, prevention and control of leukemia in the future.